GSK Acquires RAPT Therapeutics for $2.2 Billion to Advance Food Allergy Drug Ozureprubart

GSK has entered a definitive agreement to acquire RAPT Therapeutics for $58 per share, valuing the company at approximately $2.2 billion in equity value, with a net upfront investment of $1.9 billion after cash acquired1 2 4 5.

The acquisition grants GSK global rights to ozureprubart, a Phase IIb long-acting anti-IgE monoclonal antibody for prophylactic protection against food allergies, excluding China, Taiwan, Macau, and Hong Kong1 2 4 5.

The deal is one of the first major pharma acquisitions of 2026, aimed at bolstering GSK's immunology pipeline amid upcoming patent cliffs1 3.

The transaction involves a cash tender offer expected to commence within 10 business days, with closure anticipated in Q1 2026, subject to customary conditions including Hart-Scott-Rodino approval2 6.

Ozureprubart is under investigation in the Phase IIb prestIgE study (NCT07220811), enrolling patients in the US, Australia, and Canada, with data readout expected in 20271.

RAPT shares surged over 60% in pre-market trading following the announcement, from a prior close of $35.101 4 5.